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Review Article
Summary
The COVID-19 pandemic caused by SARS-CoV-2 has far-reaching direct and indirect 
medical consequences. These include both the course and treatment of diseases. It is 
becoming increasingly clear that infections with SARS-CoV-2 can cause considerable 
COVID-19 and immunological 
regulations – from basic and 
translational aspects to clinical 
implications
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited and is not used for commercial purposes.
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
4
9
4
9
6
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
Review Article COVID-19 and immunological regulations
796 © 2020 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft. | JDDG | 1610-0379/2020/1808
SARS-CoV-2/COVID-19 and immunity: 
Our present view in a nutshell
The coronavirus SARS-CoV-2 can cause COVID-19 disease 
in infected patients [1, 2]. This new disease holds the world 
in thrall in many ways and it confronts our society with un-
precedented challenges [3]. As impressively demonstrated by 
the more than 35,000 scientific publications on COVID-19 
in only seven months (MedLine access 29. July 2020), the 
amount of data available is increasing rapidly.
The virus preferentially enters macrophages, type II 
pneumocytes, pericytes and muscle cells, thus causing direct 
organ damage, especially in patients with pre-existing co-
morbid conditions. The first symptoms of COVID-19 usually 
manifest five to six days after infection [4, 5]. Shedding of 
virus particles begins two to three days before the onset of 
symptoms, and although the virus can be detected for up to 
37 days, infectivity decreases significantly about ten days af-
ter the first symptoms [4, 6, 7]. IgM against SARS-CoV-2 
develops about eight to twelve days after infection and di-
sappears after about twelve weeks. The IgG seroconversion 
occurs after approximately 14 days, and IgG lasts longer 
than IgM [8–10]. Antibodies against SARS-CoV-2 are likely 
protective, since passive transfer of convalescent plasma can 
attenuate the course of disease in severely affected patients 
with COVID-19 [11–15]. However, serious pulmonary com-
plications in some patients may be related to adaptive immu-
nity [16–18].
On the one hand, elements of innate immunity play 
a decisive role in whether and how COVID-19 develops 
after infection with SARS-CoV-2 [8, 17, 19, 20]. Cellular 
components (such as natural killer cells, γδ-T cells and 
cells of myeloid origin) work together with humoral factors 
(complement and coagulation system, natural antibodies, 
cytokines, chemokines and pathogen-binding glycans) to 
mount an innate antiviral immune response [21–23]. On the 
other hand, profound changes in innate and acquired im-
mune responses, even up to an uncontrolled cytokine storm, 
may occur during the disease and in case of complications 
[24]. As patients with immune-mediated disorders or immu-
nomodulatory therapies have altered immune functions, it 
is conceivable that this impacts the course of the infection 
and vice versa (Figure 1).
immunological alterations, which particularly also affect pathogenetically and/or the-
rapeutically relevant factors.
Against this background we summarize here the current state of knowledge on 
the interaction of SARS-CoV-2/COVID-19 with mediators of the acute phase of inflam-
mation (TNF, IL-1, IL-6), type 1 and type 17 immune responses (IL-12, IL-23, IL-17, IL-36), 
type 2 immune reactions (IL-4, IL-13, IL-5, IL-31, IgE), B-cell immunity, checkpoint regu-
lators (PD-1, PD-L1, CTLA4), and orally druggable signaling pathways (JAK, PDE4, cal-
cineurin). In addition, we discuss in this context non-specific immune modulation by 
glucocorticosteroids, methotrexate, antimalarial drugs, azathioprine, dapsone, myco-
phenolate mofetil and fumaric acid esters, as well as neutrophil granulocyte-media-
ted innate immune mechanisms.
From these recent findings we derive possible implications for the therapeutic 
modulation of said immunological mechanisms in connection with SARS-CoV-2/
COVID-19. Although, of course, the greatest care should be taken with patients with 
immunologically mediated diseases or immunomodulating therapies, it appears that 
many treatments can also be carried out during the COVID-19 pandemic; some even 
appear to alleviate COVID-19.
Figure 1 Schematic representation of immune activation in 
COVID-19. SARS-CoV-2 preferentially attacks pneumocytes, 
pericytes and muscle cells. Numerous mediators, for example 
IL-1, IL-6 and TNF, are induced mainly via the interferon and 
NF-κB signaling pathways. A balanced immune response leads 
to elimination of the viruses and healing (left side). In predis-
posed patients, however, a so-called cytokine storm with an 
uncontrolled increase in proinflammatory mediators can also 
occur. This may lead to severe organ damage (right side).
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Research on immunological regulatory pathways has 
led to many selectively acting biologicals and small mo-
lecule drugs which have revolutionized the treatment of 
chronic inflammatory diseases and tumor therapy. In ad-
dition, numerous conventional drugs also interfere with 
immunological processes, albeit usually in a less specific 
way. In this situation it is quite conceivable that infections 
with SARS-CoV-2 influence relevant immunoregulatory 
pathways and therapies. Neutrophilia and lymphopenia as 
well as elevated serum concentrations of numerous cytoki-
nes and chemokines including therapeutically or pathoge-
netically relevant mediators have been described [19, 25, 
26]. We currently assume that many immunological medi-
ators altered by COVID-19 are not primarily involved in 
virus elimination [27].
A pattern of immunological consequences of an infecti-
on with SARS-CoV-2 is now emerging that makes it approp-
riate to rethink some diseases and their treatments (Figure 2). 
It is, however, not easily predictable from the outset whether 
and how an infection with SARS-CoV-2 would interfere 
with a given therapy or signaling pathway. Some anti-inflam-
matory therapies might even have positive effects in severe 
COVID-19 cases. Insight into how immunological mechanis-
ms are influenced by SARS-CoV-2 would therefore be rele-
vant for disease management (Table 1). It seems important 
to us to outline specifics of the new knowledge that touch on 
pathogenesis or therapy.
SARS-CoV-2/COVID-19 and primary 
acute phase mediators (TNF, IL-1, IL-6)
The infection primarily activates two signaling cascades of 
innate immunity, the interferon and the NF-κB pathways 
[28]. Consequently, serum and tissue levels of IL-1, TNF and 
IL-6 are elevated in COVID-19 patients [19, 29]. Indeed, the 
balance of proinflammatory cytokines seems to impact the 
outcome. IL-1, IL-6 and TNF might be protective as they fa-
cilitate killing of virus-infected host cells by CD8+ T cells and 
phagocytes. They also promote the production of virus-spe-
cific antibodies. However, excessive levels of these cytokines 
can induce the potentially fatal “cytokine storm” [30].
Th1 cells can stimulate CD14+CD16+ monocytes to pro-
duce IL-6 and differentiate into tissue macrophages. This 
causes T cell exhaustion and tissue cell death [20, 31]. Exces-
sively high levels of IL-6 thus facilitate acute respiratory dist-
ress as well as cardiovascular damage [32]. Clinically, increa-
sed levels of IL-6 predict severe courses and complications 
of COVID-19 [33, 34]. Moreover, tocilizumab (a humani-
zed IL-6 receptor-directed antibody) impressively alleviated 
COVID-19 in 20 critically ill patients [35]. Within five days, 
oxygen could be reduced, and after 15 days, patients were 
discharged with improved lymphocyte counts and CRP. Ad-
verse events were not observed. However, the results of this 
small non-controlled study need to be confirmed in larger 
controlled trials. In any case, as far as we know, IL-6 seems 
to be important for the course of a SARS-CoV-2 infection.
IL-1α/β is another target relevant for macrophage-as-
sociated inflammation. When nine patients with acute CO-
VID-19 pneumonia were treated with anakinra, a human 
IL-1 receptor antagonist, all except one improved, were 
non-feverish from day 3 and showed decreased CRP levels 
together with good clinical outcomes [36]. This is in line with 
earlier results in septic patients [37]. Trials targeting IL-1 in 
patients with COVID-19 are underway [38].
Reports about anti-TNF treatment are not available yet, 
clinical trials are ongoing. However, COVID-19 patients 
with pre-existing inflammatory bowel disease (IBD) had bet-
ter outcomes if they were on anti-TNF treatment compared 
to corticosteroids [39].
Thus, it appears that specific targeting of the proinflam-
matory cytokines IL-1, IL-6 and TNF as part of the cytokine 
storm is beneficial for COVID-19 patients with pneumonia.
SARS-CoV-2/COVID-19 and type 1/type 17 
immunity (IL-12/IL-23, IL-17, IL-36)
In terms of T cell mediated immunity, IL-12 predominantly 
induces Th1 immune responses, whereas IL-23 contributes to 
Figure 2 Potential influence of immunomodulatory therapies 
on COVID-19. In COVID-19 patients treated with immunomo-
dulatory drugs, different effects can occur, which must be 
weighed against each other, as there is a fine-tuned balance 
of possible beneficial and detrimental effects. Some of these 
are schematically depicted here. For example, immunomo-
dulators could influence cytokine formation and action, virus 
entry into cells, thromboembolic events or lymphocyte fun-
ctions. On the other hand, the course of immune-mediated 
diseases could also be altered by infection with SARS-CoV-2. 
Many aspects of how drug therapies influence the immunolo-
gical balance are not yet known. Nevertheless, it is becoming 
apparent that some specific therapies, such as blocking IL-6, 
can positively influence the excessive immune response trig-
gered by COVID-19. On the other hand, checkpoint inhibitors 
could act synergistically with the immune activation in CO-
VID-19. Further details are explained in the text.
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Table 1 Synopsis of immunological pathways and mechanisms that can potentially interfere with SARS-CoV-2 infection. The 
table lists primarily those immunological pathways for which approved therapeutic compounds are available.
Immunological 
factors that can 
be regulated
Impact of COVID-19 or infection 
with SARS-CoV-2 on indicated 
pathway
Selected approved therapeutic 
compound(s)
Potential interference of SARS-
CoV-2 infection with targeting 
of indicated pathway
TNF Upregulated in COVID-19 – Infliximab
– Adalimumab
– Golimumab
– Etanercept
– Certolizumab pegol
No specific trials yet; better out-
come of COVID-19 in IBD patients 
on TNF blockers compared to 
glucocorticoids
IL-1 Induced in COVID-19 – Anakinra (IL-1RA)
– Canakinumab (anti-IL-1β)
– Rilonacept
Inhibition alleviated severe CO-
VID-19 symptoms
IL-6 Induced in COVID-19, potential 
prognostic marker
– Tocilizumab (anti IL-6R) Inhibition alleviated severe CO-
VID-19 symptoms
IL-12 Upregulated in one study but not 
in another; no dependence on the 
severity of COVID-19 disease, no 
change during infection
– Ustekinumab (anti IL-12/IL-
23p40)
No clinical data yet
IL-23 Possibly upregulated, transcripti-
on downregulated in PBMC
– Ustekinumab (anti IL-12/IL-
23p40)
– Guselkumab (anti-IL-23p19)
– Risankizumab (anti-IL-23p19)
– tildrakizumab (anti-IL-23p19)
No clinical data yet
IL-17 Increased serum concentration 
in COVID-19; no association with 
disease severity
– Secukinumab (anti-IL-17A)
– Ixekizumab (anti-IL-17A)
– Brodalumab (anti-IL-17R)
No clinical data yet
IL-4/IL-13 No significant change – Dupilumab (anti IL4/IL-13)
– Tralokinumab (anti IL-13)
– Lebrikizumab (anti-IL-13)
No data indicating increased risk 
of patients with atopic dermatitis 
for/with SARS-CoV-2 infection; 
blocking type 2 cytokines wi-
thout negative outcome in single 
COVID-19 infections.
IL-5 No significant change – Mepolizumab (anti-IL-5)
– Benralizumab (anti-IL-5)
– Reslizumab (anti-IL-5)
Treating asthma with IL-5 inhibiti-
on and sparing steroids potentially 
of benefit in COVID-19 infections
IL-31 No significant change – Nemolizumab (anti-IL-31RA) No clinical data
IgE No significant change – Omalizumab (anti-IgE)
– Ligelizumab (anti-IgE)
No clinical data
B-cells/CD20 No data reported – Rituximab (anti-CD20) No negative effect of CD20 
blockade on the resolution of 
COVID-19
checkpoint 
 regulators
PD-1 expression possibly elevated 
in COVID-19
– Ipilimumab (anti-CTLA-4)
– Nivolumab (anti-PD-1)
– Pembrolizumab (anti-PD-1)
– Avelumab (anti-PD-L1)
– Cemiplimab (anti-PD-L1)
Potential synergism between 
SARS-CoV-2 infection and im-
mune checkpoint inhibitors, no 
actual data
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Immunological 
factors that can 
be regulated
Impact of COVID-19 or infection 
with SARS-CoV-2 on indicated 
pathway
Selected approved therapeutic 
compound(s)
Potential interference of SARS-
CoV-2 infection with targeting 
of indicated pathway
JAK COVID-19-induced cytokine pro-
duction mediated by JAK-STAT 
pathway
– Tofacitinib (anti-JAK1/3)
– Baricitinib (anti-JAK1/2)
– Upadacitinib (anti-JAK1/2)
Beneficial effect of JAK inhibitors 
on COVID-19-associated immune 
hyperactivation is likely
PDE4 No data reported – Apremilast No clinical data yet
Calcineurin, 
 cyclophilins
– Cyclosporin A
– Tacrolimus
– Sirolimus
Limited data, possibly beneficial 
in COVID-19
Pleiotropic (bro-
ad or nonspe-
cific) immuno-
modulation or 
-suppression
– Glucocorticosteroids (GC)
– Methotrexate
– Azathioprine
– Mycophenolate mofetil/ 
 Mycophenolic acid
– Fumaric acid esters
– Dapsone
– Colchicine
– Antimalarials 
 (4-Aminoquinolines)
– Immunoglobulins
No general contraindication;
continue necessary therapies, no 
evidence-based data in COVID-19
Innate immune 
responses, neut-
rophil functions
Neutrophilia and (probably) 
 NETosis in COVID-19
– DNase I (cleaves free DNA) No data, possibly beneficial
Th17 immunity [40]. Various viruses including SARS-CoV-1 
from the 2003 outbreak can induce IL-12 [41, 42]. Compa-
ring 50 COVID-19 patients with eight healthy controls re-
vealed an increase of a multitude of pro-inflammatory cyto-
kines and chemokines including IL-12p70 and IL-12p40. The 
upregulation was independent of the disease severity and did 
not change up to day 15 [26]. Another study did not detect 
increased serum levels of IL-12p70 in 60 COVID-19 patients 
compared to four healthy controls [19]. Potential confoun-
ding factors in both studies were the heterogeneity of the CO-
VID-19 patients and the low number of controls.
In a transcriptomic study, IL-23 tended to be down-
regulated in peripheral blood mononuclear cells (PBMC) 
of COVID-19 patients [43]. Collectively, an infection with 
SARS-CoV-2 likely leads to enhanced IL-12 and IL-23 serum 
concentrations.
Th17 cells, Tc17 cells, subsets of innate lymphocytes in-
cluding ILC3 and natural killer T cells, and cells of myeloid 
origin are sources of IL-17 [44–46]. IL-17 contributes to an-
ti-infectious responses and to cytokine and chemokine pro-
duction particularly at epithelial sites including the lung [47]. 
The incorporation of IL-17 in some large viruses, such as 
HSV, suggests a role in anti-viral immunity, and virus- specific 
IL-17 producing T cells have been detected [48]. Howe-
ver, IL-17 enhances the respiratory-syncytial-virus-induced 
production of neutrophil-attracting chemokines, thereby in-
creasing neutrophil recruitment into the lung [49]. A study of 
41 COVID-19 patients demonstrated a significant increase of 
IL-17 serum concentration of intensive care unit (ICU) pati-
ents compared to healthy subjects but not to non-ICU pati-
ents [19]. Comparison of 123 COVID-19 patients with mild 
versus severe symptoms did not show significant differences 
[50]. Like IL-12 and IL-23, the serum concentration of IL-17 
seems to increase in COVID-19 patients, but this needs to be 
validated in larger trials.
Transcriptomics of bronchoalveolar lavage fluid (BAL) 
and PMBC of small numbers of COVID-19 patients and he-
althy controls identified complement activation and humoral 
immune responses among the top-differentially regulated 
pathways [43]. While several cytokines were differentially 
expressed, molecules of the IL-36 pathway were not among 
them. Although these data have not been validated, IL-36 
seems to be unaffected by COVID-19.
SARS-CoV-2/COVID-19 and type 2 
 immunity (IL-4, IL-13, IL-5, IL-31, IgE)
Type 2 cytokines such as IL-4, IL-13, IL-5 and IL-31 as well 
as IgE have scarcely been studied in SARS-CoV-2 infections. 
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Theoretically, they may even oppose COVID-19-associated 
inflammation depending on the phase of the infection. They 
could weaken the early immune defense as observed in atopic 
dermatitis (AD) and herpes viruses or modulate later phases. 
Type 2 cytokines are not part of the hyperinflammation in 
the lungs of COVID-19 patients [30] but may modulate the 
cytokine storm as we know that these mediators can inhibit 
type 1 and type 17 immune responses [51]. Among hospita-
lized patients with COVID-19, those with allergic diathesis 
are only a minority [52]. Until reliable registry entries are 
available, data on targeted therapies with reported side- 
effects and safety issues in other viral infections could help us 
to approach a possible risk in SARS-CoV-2 infected patients.
Likewise, no data on SARS-CoV-2 infections in AD pa-
tients, a prototypic IL-4/IL-13-mediated type 2 disease, is 
available yet. AD patients often suffer from comorbid viral in-
fections as a consequence of type 2 immunity dominance [53]. 
Clinical studies indicated that dupilumab did not reduce cont-
rol of airway infection, but rather improved control of herpes 
virus infection [54]. Accordingly, two Italian studies indicate 
no increased risk of AD patients under dupilumab therapy to 
succumb to SARS-CoV-2 infection [55, 56]. Regarding IL-13 
blockade (tralokinumab, lebrikizumab), the few data available 
similarly suggest no effect on viral disease [57, 58].
Eosinophils are a hallmark of type 2 diseases; their re-
duction by inhibiting IL-5 function (mepolizumab, benrali-
zumab, reslizumab) in eosinophilic asthma leads to disease 
control and helps to reduce steroids. A positive effect of IL-5 
inhibition was postulated on the course of COVID-19 in pa-
tients with asthma [59]. Like IL-4 and IL-13, IL-5 has not 
been attributed an essential role in COVID-19.
Another type 2 cytokine that can be targeted in patients 
with intense pruritus is IL-31. Within the limited patient co-
hort treated with nemolizumab, no increased risk for upper 
airway infections, but gastrointestinal and musculoskeletal 
side effects occurred [60]. The development of peripheral 
edema under therapy is not well understood [61].
Targeting IgE with omalizumab in asthma or chronic 
spontaneous urticaria patients did not increase upper airway 
infections [62]. IgE is low or not detectable under normal 
conditions, and it is not secreted in response to SARS-CoV-2 
infection.
There is currently no scientific evidence to suggest that 
inhibition of type 2 mediators in patients with the respective 
diseases should be avoided due to the SARS-CoV-2 pandemic.
SARS-CoV-2/COVID-19 and B-cell 
immunity
The anti-CD20 antibody rituximab, approved for the treat-
ment of pemphigus vulgaris and B cell lymphoma, depletes 
B lymphocytes for months resulting in abrogation of humo-
ral responses. It may therefore be problematic for patients 
infected with SARS-CoV-2. On the other hand, production 
of high levels of SARS-CoV anti-spike IgG may contribute 
to a more severe course of COVID-19 [63], which might be 
avoided when B cells are depleted. Two patients suffering 
from granulomatosis with polyangiitis who had been trea-
ted with rituximab before observed quite rapid resolution of 
COVID-19 [64, 65]. While systematic studies on COVID-19 
and B cell depletion are not available, the application of 
rituximab during the pandemic needs to be considered very 
carefully in each individual case.
SARS-CoV-2/COVID-19 and immune 
checkpoint regulators
While immune checkpoint molecules can be expressed con-
stitutively, induction by TCR binding or cytokines is more 
common [66, 67]. They control important balances within 
the immune system, the modulation of which has revolutio-
nized anti-tumor therapies [68, 69]. Although HIV or HBV 
infections lead to increased and persistent PD-1 expression 
on T cells [70], immune checkpoint inhibitors (ICI) appear to 
be safe and effective in patients with chronic viral hepatitis 
or HIV infection [71–73]. There are no actual data on the in-
fluence of COVID-19 on expression or function of CTLA-4, 
PD-1 or PD-L1. In a cohort of patients with lung cancer, no 
association of prior exposure to PD-1 blockade and severity 
of a SARS-CoV-2 infection was found [74]. In a melanoma 
patient treated with PD-1 inhibitors no particularly severe 
course of COVID-19 occurred [75].
A not yet peer-reviewed retrospective analysis by Diao 
et al. in MedRxiV (pre-print server) found significant lym-
phopenia in 522 Chinese patients with COVID-19, which 
corroborates earlier findings in a single Chinese patient 
[76] and in a Greek cohort [77]. In the study by Diao 
et al., PD-1 expression by peripheral T cells of 14 SARS-
CoV-2-infected patients was significantly higher compared 
to three healthy donors and seemed to correlate with di-
sease severity. Increasing PD-1 and TIM-3 expression on 
T cells over time correlated with the severity of COVID-19 
in three patients. Although preliminary, these data are in 
line with the increase of immune checkpoint molecules in 
viral infections.
Since viral infections increase the expression of check-
point molecules, and ICI can trigger a cytokine storm (cy-
tokine release syndrome) similar to COVID-19 [78], it is 
conceivable that ICI could worsen the course of COVID-19 
or, conversely, COVID-19 could increase the (desired and 
undesired) effects of ICI [78, 79]. Interestingly, the cytokine 
storm induced by either COVID-19 or ICI can be successfully 
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treated with tocilizumab (anti-IL-6R) [80, 81]. Thus, the ICI 
mode of action and COVID-19 share remarkable similarities 
with both leading to adverse immune hyperactivation.
SARS-CoV-2/COVID-19 and orally target-
ed molecules (JAK, PDE4, calcineurin)
Patients treated with small molecule inhibitors of immuno-
logical pathways might be vulnerable in the current pande-
mic. However, direct evidence is missing, whether they are 
at higher risk of acquiring SARS-CoV-2, of developing a 
more severe disease course, or of generating a non-protec-
tive anti-viral immune response. It is also conceivable that 
some small molecules can alleviate the cytokine storm in 
COVID-19 patients.
As JAK inhibitors (JAKi) prevent signaling of many 
cytokine receptors, common infections are frequent seve-
re adverse events and serious herpes zoster is a drug class- 
specific risk [82]. Tofacitinib (JAK1/3 inhibitor), baricitinib 
and upadacitinib (both JAK1/2 inhibitors) are currently 
approved drugs [83]. JAK2 inhibition appears to block cel-
lular entry of SARS-CoV-2 and may thus decrease the in-
fectivity in lung cells [84]. Many cytokines released during 
a COVID-19-associated cytokine storm signal via the JAK-
STAT pathway [84]. Moreover, Th17 cells likely contribute 
to this cytokine storm resulting in tissue damage and pul-
monary edema. Although JAK inhibition can weaken host 
inflammatory responses and impair hematopoiesis, therapies 
using JAKi may decrease unwanted inflammatory reactions. 
Thus, as JAKi may alleviate acute respiratory distress syn-
drome (ARDS) in COVID-19 patients, several phase 2 trials 
are currently underway.
The immunosuppressants cyclosporin (CsA) and tacro-
limus act rather selectively on T cells by inhibiting calci-
neurin phosphatase. No data is available on their effect in 
COVID-19 patients [85]. Interestingly, CsA demonstrated 
antiviral activity in vitro. It inhibits replication of some RNA 
viruses including Betacoronaviridae, which employ cyclo-
philins as chaperones and NFAT signaling. These data led to 
the speculation that CsA may ameliorate SARS. It is unclear 
whether the antiviral activity may impair the mounting of 
an immune response to coronaviruses and, consequently, in-
crease vulnerability to future infections. These immunosup-
pressants might only be successful in SARS-CoV-2-infected 
patients, if no uncontrolled viral replication occurs. Tacroli-
mus is currently being tested in a phase 3 trial for COVID-19 
lung injury.
Apremilast is a PDE4 inhibitor which increases cellular 
cyclic AMP levels, thereby controlling production of inflam-
matory cytokines in leukocytes and epithelial cells. It does 
not lead to apparent immunosuppression, and severe viral 
infections are not common adverse events. Although actual 
data are missing, apremilast, because of its overall low risk of 
severe immunological deterioration, may have a comparably 
favorable risk profile in patients with chronic inflammatory 
diseases during the current COVID19 pandemic.
SARS-CoV-2/COVID-19 and antimalarials
Hydroxychloroquine (HCQ) and chloroquine (CQ) accumu-
late in lysosomes where they inhibit endocytosis, autophagy 
and, consequently, MHC class II (auto)antigen presentation. 
They also inhibit TLR7 and TLR9 binding to the respective 
ligands (DNA, RNA), the type I interferon response, cytoki-
ne (IL-1, TNF, IL-6) and chemokine synthesis (CCL4), and 
down-regulate CD40L [86].
Several studies demonstrated in vitro antiviral activity 
of antimalarials. During the SARS 2003 outbreak caused by 
SARS-CoV-1, CQ was proposed as potential agent [87]. It 
was demonstrated later that antimalarials also impair the 
glycosylation of ACE2, the cellular receptor of SARS-CoV-1 
(and SARS-CoV-2) thus inhibiting virus entry into the cell 
[88]. Chloroquine is active against SARS-CoV-2 in vitro [89], 
and it was recommended by Chinese experts for the treat-
ment of COVID-19-associated pneumonia despite lack of cli-
nical data [90]. A small uncontrolled French study combined 
HCQ with azithromycin and reported a significant reduction 
of viral load [91]. A double-blinded randomized trial from 
Brazil was prematurely terminated after enrolling 81 of the 
intended 440 patients because of serious adverse events in-
cluding many fatalities [92]. An observational study of 1,376 
COVID-19 patients revealed no difference regarding the 
primary endpoint, freedom of intubation or death, between 
HCQ-treated and -untreated patients [93]. In view of these 
data the conducting center withdrew its institutional sugge-
stion to treat COVID-19 patients with HCQ.
The US Food and Drug Administration has issued 
“Emergence Use Authorizations” to provide CQ and HCQ 
for treating adults and teenagers when participation in clini-
cal trials is not possible [94] but later revoked those authori-
zations since on basis of newer data it is now considered un-
likely that CQ and HCQ are effective in treating COVID-19 
(https: //www.fda.gov/news-events/press-announcements/co-
ronavirus-covid-19-update-fda-revokes-emergency-use-au-
thorization-chloroquine-and; published on June 15, 2020; 
accessed on June 21, 2020). The European Medicines Agency 
recommended CQ and HCQ in the context of COVID-19 
only in clinical trials or within national emergency use pro-
grams [95]. A recent editorial on the use of HCQ for CO-
VID-19 concluded that the current data situation should 
prompt “some degree of skepticism toward the enthusiastic 
claims about chloroquine and perhaps serve(s) to curb the 
exuberant use” [96].
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It appears reasonable to continue CQ or HCQ for 
approved or long established off-label conditions when 
indicated. While the doses prescribed in dermatology are 
usually lower than in COVID-19 studies, health care pro-
fessionals should nevertheless carefully monitor their pati-
ents for adverse events and report side effects to regulatory 
authorities [86, 97].
SARS-CoV-2/COVID-19 and general 
immunosuppression
In patients with immune-mediated diseases the question ari-
ses whether immunosuppressive therapies should be main-
tained, reduced or discontinued in the context of SARS-
CoV-2. Of course, there is no general answer but three basic 
considerations: First, immunosuppression could interfere 
with infection control and thus be detrimental. Second, im-
munosuppression could support treatment by suppressing 
the COVID-19-associated immunopathology [30]. Third, 
discontinuation could trigger exacerbation of the treated un-
derlying disease, which would be harmful [98]. There is no 
evidence for an increased risk of immunosuppressed patients 
from COVID-19.
COVID-19 did not affect the hospitalization or death 
rates of psoriasis patients [99, 100]. However, there is also 
no evidence of protection of immunosuppressed patients 
from COVID-19-associated immunopathology, as reported 
for renal transplant recipients [101]. Therefore, current gui-
delines for classical immunosuppressants can be summari-
zed as follows: i) In patients without SARS-CoV-2 infection, 
immunosuppressive therapy can be continued; ii) In mild 
or asymptomatic COVID-19 cases, continuation of therapy 
should be decided on a case-by-case basis; iii) In COVID-19 
patients with severe symptoms, withdrawal of immunosup-
pressive medications is advisable; however, the final decision 
should be made by the treating physician and the ICU team.
Glucocorticosteroids
There is no general evidence that patients with SARS-CoV-2 
infection benefit from glucocorticosteroids (GC) [31, 102]. 
For instance, the use of oral GC was higher among CO-
VID-19 patients with immune-mediated inflammatory di-
sease who were hospitalized [103]. A retrospective analysis 
of COVID-19 patients receiving methylprednisolone did not 
show a beneficial clinical outcome [101]. Overall, it appears 
that systemically administered GC rather have a negative ef-
fect on the course of COVID-19. Thus, GC treatment of seve-
re SARS-CoV-2 infection is recommended only in the context 
of clinical trials [101, 104] or if indicated within a necessary 
therapy regimen [105].
Methotrexate
The relevance of methotrexate for the clinical course of CO-
VID-19 is unknown. While a case study of patients with 
immune-mediated inflammatory disease found that those ta-
king methotrexate required hospitalization more often [103], 
a systematic review – also including reports of SARS-CoV-1 
and MERS – concludes that there is no definitive evidence for 
contraindication of methotrexate in auto-immune diseases 
[100, 106].
Mycophenolate mofetil (MPM)/mycophenolic 
acid (MPA)
In vitro, MPA showed anti-viral activity against MERS-CoV 
and SARS-CoV-1 [100, 107], [108] but was detrimental in 
animal studies [109]. A psoriasis patient on MPM treatment 
experienced a very mild form of COVID-19, suggesting that 
MPM can be continued [110].
Azathioprine
In renal transplant recipients infected with SARS-CoV-2, 
patients taking azathioprine did not have higher risk of 
severe disease [98].
Dapsone and colchicine
Both agents may inhibit the cytokine storm and neutrophil 
chemotaxis to the lungs [111, 112]. However, there are no 
clinical trials available to support this hypothesis.
Dimethyl fumarate
There are also speculations about a potential therapeutic be-
nefit of dimethyl fumarate because of its ability to scavenge 
oxidative stress. Again, evidence to support this hypothesis 
is missing.
SARS-CoV-2/COVID-19 and neutrophil-
mediated innate immunity
Neutrophils as part of the innate immune system can produce 
NETs (neutrophil extracellular traps) [113]. Excessive NETosis 
can be deleterious, as NET-components are cytotoxic, immuno-
genic and pro-thrombotic [114, 115] and can damage organs 
in several diseases [38, 116], [117], which are also affected in 
severe COVID-19. Neutrophils directly or indirectly contribute 
to cytokine release, such as IL-1β or IL-6 [118], thus facilitating 
the COVID-19 cytokine storm. Hence, activated neutrophils 
and NETs may contribute to COVID-19. Indeed, neutrophilia 
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predicts poor outcome [25] and severe neutrophilic infiltrations 
were noted in patients who died from COVID-19 [38, 119].
NETs can also contribute to mucus thickening and bac-
terial superinfection in respiratory diseases such as cystic 
fibrosis [120]. Inhalative DNase I improves lung function 
through degradation of extracellular DNA [121] and could 
be a simple, effective and safe addition to the therapy of CO-
VID-19 [122].
Furthermore, NETs link immunopathology and throm-
bosis. They degrade antithrombin III, activate platelets and 
the contact pathway of coagulation. Blood clots occur in 20–
30 % of patients with COVID-19 [123]. These patients are 
not only prone to large thromboembolic events but also to 
microvascular thrombosis in many organs [38, 124]. In ani-
mal models, systemic DNase I treatment dissolved NETs and 
restored organ perfusion [125], which fuels corresponding 
speculations in COVID-19. Thus, targeting neutrophils and 
NETs could potentially ameliorate COVID-19. In addition to 
the abovementioned DNAse I, a number of other compounds 
are currently being developed and may disrupt detrimental 
neutrophil functions in the future.
Conclusions
According to our current state of knowledge, there is no 
evidence-based reason to discontinue or not start necessary 
immunomodulatory therapies in patients with inflammat-
ory diseases or tumors during the SARS-CoV-2 pandemic. 
But of course – as is often the case in uncertain situations 
with insufficient and constantly evolving data – we must be 
careful and vigilant. As the example of 4-aminoquinolines 
shows, perspectives can change rapidly. In any case, there 
is no general recommendation regarding discontinuation of 
immunomodulatory therapies. Some cytokine inhibitors or 
other immune modulators could even have a positive effect 
on the course of COVID-19 disease. Depending on the spe-
cific therapy, the possible interaction with SARS-CoV-2-in-
duced effects must be considered in a differentiated way and 
often individual case decisions must be made. Of course, our 
knowledge is in a state of flux, and our considerations de-
lineated herein are based on the currently emerging pattern 
of immunological changes in COVID-19. Some of our state-
ments should therefore be regarded as preliminary or a mat-
ter of opinion, respectively. We must remain vigilant and we 
would encourage our colleagues to critically evaluate their 
observations in patients infected with SARS-CoV-2.
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